Faisal Khurshid
Stock Analyst at Leerink Partners
(2.23)
# 2,765
Out of 4,906 analysts
22
Total ratings
52.94%
Success rate
-3.48%
Average return
Main Sectors:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Outperform | $88 → $102 | $88.63 | +15.09% | 2 | Jul 10, 2025 | |
| ABCL AbCellera Biologics | Assumes: Outperform | $5 | $5.15 | -2.91% | 1 | Jul 7, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Perform | $3 → $1 | $0.76 | +30.99% | 2 | Apr 14, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $45 | $16.35 | +175.23% | 1 | Apr 8, 2025 | |
| NRIX Nurix Therapeutics | Initiates: Market Perform | $16 | $11.25 | +42.22% | 1 | Mar 17, 2025 | |
| STTK Shattuck Labs | Initiates: Outperform | $4 | $0.77 | +420.90% | 1 | Mar 17, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Market Perform | $33 → $2 | $1.46 | +37.46% | 2 | Mar 3, 2025 | |
| ATYR aTyr Pharma | Initiates: Outperform | $16 | $5.71 | +180.21% | 1 | Feb 18, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $60 | $45.17 | +32.83% | 2 | Dec 27, 2024 | |
| ANIP ANI Pharmaceuticals | Initiates: Outperform | $80 | $65.30 | +22.51% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $1.72 | +772.09% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $7 | $6.84 | +2.34% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $45 | $19.67 | +128.81% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $24 | $32.14 | -25.33% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.23 | +469.11% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $3.82 | +109.42% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $5 | $0.93 | +436.71% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $11 | $3.85 | +185.71% | 1 | Mar 21, 2023 |
Rhythm Pharmaceuticals
Jul 10, 2025
Maintains: Outperform
Price Target: $88 → $102
Current: $88.63
Upside: +15.09%
AbCellera Biologics
Jul 7, 2025
Assumes: Outperform
Price Target: $5
Current: $5.15
Upside: -2.91%
Ironwood Pharmaceuticals
Apr 14, 2025
Maintains: Market Perform
Price Target: $3 → $1
Current: $0.76
Upside: +30.99%
Spyre Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: $45
Current: $16.35
Upside: +175.23%
Nurix Therapeutics
Mar 17, 2025
Initiates: Market Perform
Price Target: $16
Current: $11.25
Upside: +42.22%
Shattuck Labs
Mar 17, 2025
Initiates: Outperform
Price Target: $4
Current: $0.77
Upside: +420.90%
Pliant Therapeutics
Mar 3, 2025
Downgrades: Market Perform
Price Target: $33 → $2
Current: $1.46
Upside: +37.46%
aTyr Pharma
Feb 18, 2025
Initiates: Outperform
Price Target: $16
Current: $5.71
Upside: +180.21%
Kymera Therapeutics
Dec 27, 2024
Maintains: Outperform
Price Target: $60
Current: $45.17
Upside: +32.83%
ANI Pharmaceuticals
Dec 11, 2024
Initiates: Outperform
Price Target: $80
Current: $65.30
Upside: +22.51%
Nov 4, 2024
Initiates: Outperform
Price Target: $15
Current: $1.72
Upside: +772.09%
Sep 9, 2024
Assumes: Outperform
Price Target: $7
Current: $6.84
Upside: +2.34%
Sep 9, 2024
Assumes: Outperform
Price Target: $45
Current: $19.67
Upside: +128.81%
Sep 9, 2024
Initiates: Market Perform
Price Target: $24
Current: $32.14
Upside: -25.33%
Sep 9, 2024
Initiates: Outperform
Price Target: $7
Current: $1.23
Upside: +469.11%
Sep 9, 2024
Assumes: Outperform
Price Target: $8
Current: $3.82
Upside: +109.42%
Sep 9, 2024
Assumes: Outperform
Price Target: $5
Current: $0.93
Upside: +436.71%
Mar 21, 2023
Initiates: Outperform
Price Target: $11
Current: $3.85
Upside: +185.71%